Page 756 - Read Online

Targher et al. Hepatoma Res 2020;6:64 I http://dx.doi.org/10.20517/2394-5079.2020.71 Page 9 of 9

28. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32-42.
29. Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ
2018;362:k2734.
30. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28.
31. Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 2019;70:711-24.
32. Lin S, Huang J, Wang M, Kumar R, Liu Y, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int
2020:2082-9.
33. Targher G. Concordance of MAFLD and NAFLD diagnostic criteria in “real-world” data. Liver Int 2020; doi: 10.1111/liv.14623.
34. Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, et al. Global epidemiology of lean non-alcoholic fatty liver disease: a systematic
review and meta-analysis. J Gastroenterol Hepatol 2020; doi: 10.1111/jgh.15156.
35. Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, et al. From NAFLD to MAFLD: implications of a premature change in
terminology. Hepatology 2020; doi: 10.1002/hep.31420.
36. Yki-järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol
2014;2:901-10.
37. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other
extrahepatic diseases. Gut 2017;66:1138-53.
38. Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Lancet Diabetes Endocrinol 2019;7:313-24.
39. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms
and pharmacological implications. Gut 2020;69:1691-705.
40. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol 2020;72:785-801.
41. Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease.
Metabolism 2020:154170.
42. Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, et al. Low awareness of nonalcoholic fatty liver disease among patients
at high metabolic risk. J Clin Gastroenterol 2015;49:e6-10.
43. Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, et al. Insights from qualitative research on NAFLD awareness
with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 2020;20:1142.